Not Signed In - Spectrum Pharmaceuticals Announces Satraplatin Data Presentation At The American Society Of Clinical Oncology Prostate Cancer Symposium
Sat, 24 Feb 2007 08:00 AM EST
... Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that final progression-free survival (PFS) results for the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), a double-blind, randomized Phase 3 registrational trial, will be presented today at the ASCO Prostate Cancer Symposium in Orlando, Florida. [click link for full article] ...
Related Topics
- Clinical Trials
- Prostate Cancer
- Prostate
- Cancer
- Cancers
- Psychopharmacology
- Data & Statistics
- Data Analysis
- Radiation Therapy
- Autism
- Epidemiology
- Biopsy of the Prostate
- National Data
- Pharmacology
- Epidemiology & Prevention of Vaccine-Preventable Diseases
- Bone Cancer
- Pancreatic Cancer
- Autism Spectrum Disorders
- Prostate Diseases
- Infectious Diseases
email this page
print this page
bookmark this page
feedback on this page
